This company has been marked as potentially delisted and may not be actively trading. Blue Water Acquisition Corp. III (BLUW) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock BLUW vs. PRME, PLX, IKT, ZIVO, CVM, IZTC, CRTX, JATT, FNCH, and ALVRShould you be buying Blue Water Acquisition Corp. III stock or one of its competitors? The main competitors of Blue Water Acquisition Corp. III include Prime Medicine (PRME), Protalix BioTherapeutics (PLX), Inhibikase Therapeutics (IKT), ZIVO Bioscience (ZIVO), CEL-SCI (CVM), Invizyne Technologies (IZTC), Cortexyme (CRTX), JATT Acquisition (JATT), Finch Therapeutics Group (FNCH), and AlloVir (ALVR). These companies are all part of the "medical" sector. Blue Water Acquisition Corp. III vs. Its Competitors Prime Medicine Protalix BioTherapeutics Inhibikase Therapeutics ZIVO Bioscience CEL-SCI Invizyne Technologies Cortexyme JATT Acquisition Finch Therapeutics Group AlloVir Blue Water Acquisition Corp. III (NASDAQ:BLUW) and Prime Medicine (NYSE:PRME) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, media sentiment, profitability and dividends. Do insiders and institutionals believe in BLUW or PRME? 70.4% of Prime Medicine shares are held by institutional investors. 22.7% of Prime Medicine shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts prefer BLUW or PRME? Prime Medicine has a consensus price target of $8.92, suggesting a potential upside of 151.17%. Given Prime Medicine's stronger consensus rating and higher possible upside, analysts clearly believe Prime Medicine is more favorable than Blue Water Acquisition Corp. III.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Blue Water Acquisition Corp. III 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Prime Medicine 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.75 Is BLUW or PRME more profitable? Blue Water Acquisition Corp. III's return on equity of 0.00% beat Prime Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Blue Water Acquisition Corp. IIIN/A N/A N/A Prime Medicine N/A -107.87%-74.97% Which has preferable valuation and earnings, BLUW or PRME? Blue Water Acquisition Corp. III has higher earnings, but lower revenue than Prime Medicine. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBlue Water Acquisition Corp. IIIN/AN/AN/AN/AN/APrime Medicine$4.96M96.30-$198.13M-$1.56-2.28 Does the media prefer BLUW or PRME? In the previous week, Prime Medicine had 3 more articles in the media than Blue Water Acquisition Corp. III. MarketBeat recorded 3 mentions for Prime Medicine and 0 mentions for Blue Water Acquisition Corp. III. Prime Medicine's average media sentiment score of 0.34 beat Blue Water Acquisition Corp. III's score of 0.00 indicating that Prime Medicine is being referred to more favorably in the news media. Company Overall Sentiment Blue Water Acquisition Corp. III Neutral Prime Medicine Neutral SummaryPrime Medicine beats Blue Water Acquisition Corp. III on 9 of the 11 factors compared between the two stocks. Get Blue Water Acquisition Corp. III News Delivered to You Automatically Sign up to receive the latest news and ratings for BLUW and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BLUW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BLUW vs. The Competition Export to ExcelMetricBlue Water Acquisition Corp. IIIBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$280.36M$283.62M$5.84B$9.75BDividend YieldN/AN/A4.40%4.10%P/E RatioN/AN/A31.4326.05Price / SalesN/A563.89468.94120.52Price / CashN/A22.4425.7828.78Price / BookN/A10.439.526.07Net IncomeN/A-$115.81M$3.26B$265.39M Blue Water Acquisition Corp. III Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BLUWBlue Water Acquisition Corp. IIIN/A$9.97flatN/A+3.5%$280.36MN/A0.002PRMEPrime Medicine2.7069 of 5 stars$3.24flat$8.92+175.2%-19.7%$436.02M$4.96M-1.58234Gap UpPLXProtalix BioTherapeutics2.989 of 5 stars$1.57+2.6%$15.00+855.4%+71.5%$125.18M$61.95M-12.08200Positive NewsGap UpIKTInhibikase Therapeutics1.7507 of 5 stars$1.68-1.2%$6.50+286.9%+32.2%$124.90MN/A-0.636News CoverageZIVOZIVO Bioscience0.2672 of 5 stars$17.20-4.7%N/A+118.2%$68.86M$15.85K-3.5210Gap DownCVMCEL-SCI1.3241 of 5 stars$8.90+5.1%N/A-71.7%$61.25MN/A-18.5443Positive NewsIZTCInvizyne TechnologiesN/A$9.78+0.2%N/AN/A$61.15MN/A0.0029CRTXCortexymeN/A$1.61-3.6%N/A+147.0%$48.54MN/A-0.5455JATTJATT AcquisitionN/A$1.73-0.6%N/A-43.7%$29.84MN/A0.003High Trading VolumeFNCHFinch Therapeutics GroupN/A$12.03-3.8%N/A+17.2%$20.07MN/A-1.36190Gap DownALVRAlloVirN/A$2.57+2.8%N/A-85.4%$12.96MN/A-0.13110Gap Up Related Companies and Tools Related Companies PRME Competitors PLX Competitors IKT Competitors ZIVO Competitors CVM Competitors IZTC Competitors CRTX Competitors JATT Competitors FNCH Competitors ALVR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BLUW) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Blue Water Acquisition Corp. III Please log in to your account or sign up in order to add this asset to your watchlist. Share Blue Water Acquisition Corp. III With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access